Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.00
ARIA's Cash to Debt is ranked higher than
57% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. ARIA: 1.00 )
ARIA' s 10-Year Cash to Debt Range
Min: 1   Max: 24.17
Current: 1

1
24.17
Equity to Asset 0.13
ARIA's Equity to Asset is ranked higher than
53% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ARIA: 0.13 )
ARIA' s 10-Year Equity to Asset Range
Min: -1.37   Max: 0.84
Current: 0.13

-1.37
0.84
F-Score: 5
Z-Score: -1.09
M-Score: -0.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -151.97
ARIA's Operating margin (%) is ranked higher than
69% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. ARIA: -151.97 )
ARIA' s 10-Year Operating margin (%) Range
Min: -526300   Max: 58.61
Current: -151.97

-526300
58.61
Net-margin (%) -154.25
ARIA's Net-margin (%) is ranked higher than
69% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. ARIA: -154.25 )
ARIA' s 10-Year Net-margin (%) Range
Min: -493975   Max: 194.03
Current: -154.25

-493975
194.03
ROE (%) -132.12
ARIA's ROE (%) is ranked higher than
55% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. ARIA: -132.12 )
ARIA' s 10-Year ROE (%) Range
Min: -523.41   Max: 93.23
Current: -132.12

-523.41
93.23
ROA (%) -35.40
ARIA's ROA (%) is ranked higher than
70% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. ARIA: -35.40 )
ARIA' s 10-Year ROA (%) Range
Min: -120.13   Max: 92.14
Current: -35.4

-120.13
92.14
ROC (Joel Greenblatt) (%) -103.64
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. ARIA: -103.64 )
ARIA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2869.58   Max: 1329.95
Current: -103.64

-2869.58
1329.95
Revenue Growth (3Y)(%) 43.40
ARIA's Revenue Growth (3Y)(%) is ranked higher than
95% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. ARIA: 43.40 )
ARIA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 214.8
Current: 43.4

0
214.8
EBITDA Growth (3Y)(%) -4.70
ARIA's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ARIA: -4.70 )
ARIA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.2   Max: 36.2
Current: -4.7

-16.2
36.2
EPS Growth (3Y)(%) -2.20
ARIA's EPS Growth (3Y)(%) is ranked higher than
80% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ARIA: -2.20 )
ARIA' s 10-Year EPS Growth (3Y)(%) Range
Min: -18.1   Max: 24.7
Current: -2.2

-18.1
24.7
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ARIA Guru Trades in Q1 2014

Jim Simons 2,248,846 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Chuck Royce 516,602 sh (-24.76%)
George Soros 500,000 sh (-74.36%)
» More
Q2 2014

ARIA Guru Trades in Q2 2014

George Soros 1,000,000 sh (+100.00%)
Jim Simons 4,399,981 sh (+95.66%)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 480,602 sh (-6.97%)
» More
Q3 2014

ARIA Guru Trades in Q3 2014

Stanley Druckenmiller 1,645,000 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (-8.32%)
Jim Simons 1,252,681 sh (-71.53%)
George Soros 150,000 sh (-85.00%)
» More
Q4 2014

ARIA Guru Trades in Q4 2014

Paul Tudor Jones 27,227 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (unchged)
George Soros Sold Out
Stanley Druckenmiller Sold Out
Jim Simons 281,381 sh (-77.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.10
ARIA's P/B is ranked lower than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. ARIA: 19.10 )
ARIA' s 10-Year P/B Range
Min: 1.69   Max: 222.33
Current: 19.1

1.69
222.33
P/S 14.30
ARIA's P/S is ranked higher than
73% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. ARIA: 14.30 )
ARIA' s 10-Year P/S Range
Min: 1.71   Max: 1334
Current: 14.3

1.71
1334
EV-to-EBIT -9.78
ARIA's EV-to-EBIT is ranked higher than
86% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARIA: -9.78 )
ARIA' s 10-Year EV-to-EBIT Range
Min: -31.7   Max: 10.4
Current: -9.78

-31.7
10.4
Current Ratio 4.29
ARIA's Current Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. ARIA: 4.29 )
ARIA' s 10-Year Current Ratio Range
Min: 1.22   Max: 12.12
Current: 4.29

1.22
12.12
Quick Ratio 4.27
ARIA's Quick Ratio is ranked higher than
74% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ARIA: 4.27 )
ARIA' s 10-Year Quick Ratio Range
Min: 1.22   Max: 12.12
Current: 4.27

1.22
12.12
Days Inventory 52.71
ARIA's Days Inventory is ranked higher than
94% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARIA: 52.71 )
ARIA' s 10-Year Days Inventory Range
Min: 8.07   Max: 321.09
Current: 52.71

8.07
321.09
Days Sales Outstanding 29.08
ARIA's Days Sales Outstanding is ranked higher than
93% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. ARIA: 29.08 )
ARIA' s 10-Year Days Sales Outstanding Range
Min: 0.49   Max: 287.59
Current: 29.08

0.49
287.59

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.80
ARIA's Price/Tangible Book is ranked higher than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. ARIA: 18.80 )
ARIA' s 10-Year Price/Tangible Book Range
Min: 1.64   Max: 1133
Current: 18.8

1.64
1133
Price/Median PS Value 0.20
ARIA's Price/Median PS Value is ranked higher than
99% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ARIA: 0.20 )
ARIA' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 7.96
Current: 0.2

0.04
7.96
Earnings Yield (Greenblatt) -10.50
ARIA's Earnings Yield (Greenblatt) is ranked higher than
61% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARIA: -10.50 )
ARIA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.5   Max: 42.7
Current: -10.5

-10.5
42.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:APS.Germany, ARIA.Switzerland,
Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 16 2013 
comment on ARIA Mar 16 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
creiter note on ARIA Jan 03 2010 

More From Other Websites
3 Things Ariad Has to Do to Be Profitable in 2018 Mar 27 2015
The young & the restless: 6 who are hot Mar 27 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 25 2015
ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court Mar 25 2015
ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court Mar 25 2015
ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel Mar 24 2015
ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel Mar 24 2015
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual... Mar 19 2015
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual... Mar 19 2015
​MIT says cancer drug costs have outpaced quality increases Mar 18 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 13 2015
Activist investor at Ariad Pharmaceuticals has long history of wins Mar 11 2015
ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court Mar 10 2015
ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court Mar 10 2015
ARIAD PHARMACEUTICALS INC Financials Mar 10 2015
10-K for ARIAD Pharmaceuticals, Inc. Mar 04 2015
Is Ariad On Track To Lose More Shares? Mar 04 2015
ARIAD PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 02 2015
Why Ariad Pharmaceuticals Shares Are Undervalued Feb 24 2015
ARIAD to Present at the Cowen and Company 35th Annual Health Care Conference Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK